New drug cocktail may replace bone marrow transplant for some leukemia patients
NCT ID NCT07259707
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment for adults with a specific type of acute myeloid leukemia (FLT3-ITD AML). The goal is to see if a combination of targeted drugs (gilteritinib, venetoclax, azacitidine) followed by high-dose chemotherapy can control the disease well enough to avoid a bone marrow transplant. About 25 participants will receive the treatment and be monitored for remission and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?